Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

IRLAB is now listed on the Nasdaq Stockholm Main Market

Read more >

Latest press release

IRLAB’s Year-end report January 1 – December 31, 2020

February 24, 2021

Significant events during the fourth quarter (October 1 – December 31, 2020) In October, the US FDA accepted mesdopetam as an investigational new drug (IND). The acceptance allows IRLAB to include patients in the US in the clinical Phase IIb/III study with mesdopetam in levodopa-induced dyskinesias in Parkinson’s (PD-LIDs). Early November, patient recruitment started in […]

Read More >
Latest presentation

Interview with CEO and CFO around the recent right issue (Swedish)

December 21, 2020 Read More >